• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Dynavax Technologies Corporation (Amendment)

    2/13/24 5:04:31 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DVAX alert in real time by email
    SC 13G/A 1 tv0801-dynavaxtechnologiesco.htm SCHEDULE 13G/A dynavaxtechnologiescorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Dynavax Technologies Corp

    Title of Class of Securities:  Common Stock

    CUSIP Number:  268158201

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  268158201

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    214,270

    7.  SOLE DISPOSITIVE POWER

    8,947,934

    8.  SHARED DISPOSITIVE POWER

    327,854

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    9,275,788

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.18%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Dynavax Technologies Corp

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    2100 Powell Street, Suite 900
    Emeryville, CA 94608

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    268158201

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $DVAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DVAX

    DatePrice TargetRatingAnalyst
    2/11/2025$15.00 → $12.00Neutral → Sell
    Goldman
    2/1/2024$20.00Neutral
    Goldman
    9/27/2022$22.00Mkt Outperform
    JMP Securities
    1/6/2022$38.00Buy
    Goldman
    12/29/2021$23.00 → $28.00Buy
    HC Wainwright & Co.
    8/31/2021$20.00 → $23.00Buy
    HC Wainwright & Co.
    8/6/2021$19.00Buy
    Goldman Sachs
    8/5/2021$16.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DVAX
    Leadership Updates

    Live Leadership Updates

    See more
    • Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum

      Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement in response to the investor presentation issued by Deep Track Capital ("Deep Track"):

      5/7/25 4:45:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders

      Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board Refreshment Underscores Deep Track's Value Destructive, Short-Term Focus and Unnecessary Proxy Contest EMERYVILLE, Calif., April 17, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockhol

      4/17/25 7:15:00 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

      Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion's Board of Directors, effective as of March 15th."I am delighted to welcome Elaine and Namandjé to Recursion's Board," said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. "As the company continues to grow its clinical pipeline and enhance its platform, our new Board members' scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success."Dr. Namandjé N. Bumpus served as the

      3/18/25 8:00:00 AM ET
      $DVAX
      $RXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $DVAX
    Financials

    Live finance-specific insights

    See more
    • Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

      Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growthTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical development in 2025 and 2027, respectively Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., May 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2025.

      5/6/25 4:01:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

      EMERYVILLE, Calif., April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynav

      4/22/25 4:00:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance

      HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025Top-line results in Phase 1/2 shingles trial expected in Q3 2025Plan to initiate Phase 2 trial for plague vaccine in Q3 2025Expect completion of $200 million share repurchase program in 2025Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Feb. 20, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2024.

      2/20/25 4:01:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Dynavax Technologies Corporation

      DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      5/7/25 5:20:10 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Dynavax Technologies Corporation

      DEFA14A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      5/7/25 6:00:29 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Dynavax Technologies Corporation

      10-Q - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

      5/6/25 4:16:04 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $DVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • President & COO Novack David F exercised 10,000 shares at a strike of $6.80 and sold $140,000 worth of shares (10,000 units at $14.00) (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      3/26/25 5:04:10 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & COO Novack David F sold $190,392 worth of shares (14,020 units at $13.58), decreasing direct ownership by 63% to 8,078 units (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      3/20/25 6:15:20 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & COO Novack David F sold $471,474 worth of shares (32,764 units at $14.39), decreasing direct ownership by 60% to 22,098 units (SEC Form 4)

      4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

      3/10/25 9:44:01 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Dynavax Technologies Corporation

      SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      11/14/24 12:18:08 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Dynavax Technologies Corporation

      SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      10/24/24 4:06:57 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Dynavax Technologies Corporation

      SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

      10/16/24 9:37:13 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dynavax downgraded by Goldman with a new price target

      Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously

      2/11/25 7:05:05 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Dynavax with a new price target

      Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00

      2/1/24 6:20:13 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Dynavax with a new price target

      JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00

      9/27/22 7:39:04 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DVAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum

      Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement in response to the investor presentation issued by Deep Track Capital ("Deep Track"):

      5/7/25 4:45:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

      Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growthTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical development in 2025 and 2027, respectively Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., May 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2025.

      5/6/25 4:01:00 PM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deep Track Capital Releases Investor Presentation on Dynavax Technologies

      Highlights Opportunity to Unlock Value With Enhanced Boardroom Objectivity Details How Deep Track's Independent Nominees Will Prioritize Shareholder-Aligned Capital Allocation Decisions and Help Set Value-Maximizing Strategy in the Boardroom Visit www.RefocusDVAX.com to Download the Full Presentation Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we") one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.53% of the Company's outstanding shares, today released an investor presentation titled "The Path to Creating and Preserving Value at Dynavax." The full presenta

      5/6/25 8:00:00 AM ET
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care